These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28185577)

  • 21. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma.
    Wei JS; Greer BT; Westermann F; Steinberg SM; Son CG; Chen QR; Whiteford CC; Bilke S; Krasnoselsky AL; Cenacchi N; Catchpoole D; Berthold F; Schwab M; Khan J
    Cancer Res; 2004 Oct; 64(19):6883-91. PubMed ID: 15466177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Connectivity Map Analysis Indicates PI3K/Akt/mTOR Inhibitors as Potential Anti-Hypoxia Drugs in Neuroblastoma.
    Uva P; Bosco MC; Eva A; Conte M; Garaventa A; Amoroso L; Cangelosi D
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The l1-l2 regularization framework unmasks the hypoxia signature hidden in the transcriptome of a set of heterogeneous neuroblastoma cell lines.
    Fardin P; Barla A; Mosci S; Rosasco L; Verri A; Varesio L
    BMC Genomics; 2009 Oct; 10():474. PubMed ID: 19832978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolomic profiling in neuroblastoma.
    Quintás G; Yáñez Y; Gargallo P; Juan Ribelles A; Cañete A; Castel V; Segura V
    Pediatr Blood Cancer; 2020 Mar; 67(3):e28113. PubMed ID: 31802629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
    Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
    Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The von Hippel-Lindau tumor suppressor gene expression level has prognostic value in neuroblastoma.
    Hoebeeck J; Vandesompele J; Nilsson H; De Preter K; Van Roy N; De Smet E; Yigit N; De Paepe A; Laureys G; Påhlman S; Speleman F
    Int J Cancer; 2006 Aug; 119(3):624-9. PubMed ID: 16506218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome.
    Fischer M; Oberthuer A; Brors B; Kahlert Y; Skowron M; Voth H; Warnat P; Ernestus K; Hero B; Berthold F
    Clin Cancer Res; 2006 Sep; 12(17):5118-28. PubMed ID: 16951229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Boolean modeling identifies Greatwall/MASTL as an important regulator in the AURKA network of neuroblastoma.
    Dahlhaus M; Burkovski A; Hertwig F; Mussel C; Volland R; Fischer M; Debatin KM; Kestler HA; Beltinger C
    Cancer Lett; 2016 Feb; 371(1):79-89. PubMed ID: 26616283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrative analysis with machine learning identifies diagnostic and prognostic signatures in neuroblastoma based on differentially DNA methylated enhancers between INSS stage 4 and 4S neuroblastoma.
    Li S; Mi T; Jin L; Liu Y; Zhang Z; Wang J; Wu X; Ren C; Wang Z; Kong X; Liu J; Luo J; He D
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):148. PubMed ID: 38512513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mixture classification model based on clinical markers for breast cancer prognosis.
    Zeng T; Liu J
    Artif Intell Med; 2010; 48(2-3):129-37. PubMed ID: 20005686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. β-1,4-Galactosyltransferase III enhances invasive phenotypes via β1-integrin and predicts poor prognosis in neuroblastoma.
    Chang HH; Chen CH; Chou CH; Liao YF; Huang MJ; Chen YH; Wang WJ; Huang J; Hung JS; Ho WL; Jeng YM; Che MI; Lee H; Lu MY; Yang YL; Jou ST; Lin DT; Lin KH; Hsu WM; Huang MC
    Clin Cancer Res; 2013 Apr; 19(7):1705-16. PubMed ID: 23444218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [N-myc gene copies in children with neuroblastoma and its clinical significance].
    Ma XL; Gong LP; Zhou CJ; Zhang DW; Jin M; Wang HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1447-51. PubMed ID: 23257451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prognostic metabolism-related gene signature associated with the tumor immune microenvironment in neuroblastoma.
    Yu X; Xu C; Zou Y; Liu W; Xie Y; Wu C
    Am J Cancer Res; 2024; 14(1):253-273. PubMed ID: 38323276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome.
    Kim DK; Alvarado CS; Abramowsky CR; Gu L; Zhou M; Soe MM; Sullivan K; George B; Schemankewitz E; Findley HW
    Pediatr Dev Pathol; 2005; 8(6):621-9. PubMed ID: 16328668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic impact of gene expression-based classification for neuroblastoma.
    Oberthuer A; Hero B; Berthold F; Juraeva D; Faldum A; Kahlert Y; Asgharzadeh S; Seeger R; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Vermeulen J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Weber A; Christiansen H; Grundy RG; Schardt K; Schwab M; Eils R; Warnat P; Kaderali L; Simon T; Decarolis B; Theissen J; Westermann F; Brors B; Fischer M
    J Clin Oncol; 2010 Jul; 28(21):3506-15. PubMed ID: 20567016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PRAF2 stimulates cell proliferation and migration and predicts poor prognosis in neuroblastoma.
    Yco LP; Geerts D; Koster J; Bachmann AS
    Int J Oncol; 2013 Apr; 42(4):1408-16. PubMed ID: 23440329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma.
    Tang XX; Zhao H; Robinson ME; Cohen B; Cnaan A; London W; Cohn SL; Cheung NK; Brodeur GM; Evans AE; Ikegaki N
    Proc Natl Acad Sci U S A; 2000 Sep; 97(20):10936-41. PubMed ID: 10984508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study.
    Vermeulen J; De Preter K; Naranjo A; Vercruysse L; Van Roy N; Hellemans J; Swerts K; Bravo S; Scaruffi P; Tonini GP; De Bernardi B; Noguera R; Piqueras M; Cañete A; Castel V; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Michon J; Combaret V; Fischer M; Oberthuer A; Ambros PF; Beiske K; Bénard J; Marques B; Rubie H; Kohler J; Pötschger U; Ladenstein R; Hogarty MD; McGrady P; London WB; Laureys G; Speleman F; Vandesompele J
    Lancet Oncol; 2009 Jul; 10(7):663-71. PubMed ID: 19515614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of hypoxia on the tumor phenotype: the neuroblastoma and breast cancer models.
    Holmquist L; Löfstedt T; Påhlman S
    Adv Exp Med Biol; 2006; 587():179-93. PubMed ID: 17163166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification.
    Oberthuer A; Berthold F; Warnat P; Hero B; Kahlert Y; Spitz R; Ernestus K; König R; Haas S; Eils R; Schwab M; Brors B; Westermann F; Fischer M
    J Clin Oncol; 2006 Nov; 24(31):5070-8. PubMed ID: 17075126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.